移植后EB病毒相关淋巴细胞增殖性疾病研究进展  

Progress of EB virus related post-transplantation lymphoproliferative diseases

作　　者：张兵[1] 闫志凌[1] 徐开林[1] 

机构地区：[1]徐州医学院附属医院血液科,221002

出　　处：《白血病．淋巴瘤》2017年第8期498-502,共5页Journal of Leukemia & Lymphoma

基　　金：国家自然科学基金（81300399）;江苏省重点研发计划（BL2015625）

摘　　要：EB病毒相关的淋巴细胞增殖性疾病（EBV-PTLD）是异基因造血干细胞移植（allo-HSCT）后的一种罕见且可能致命的并发症,临床上常表现为不明原因的发热、淋巴结肿大、肝脾大、咽炎及中枢神经系统症状等,进展迅速,病死率高.由于allo-HSCT技术在治疗复杂难治血液病方面日渐成熟,因此为预防移植物抗宿主病（GVHD）的发生而加强免疫抑制剂的使用,使得PTLD的发病率越来越高.目前对于PTLD的治疗,除了常规的治疗措施,如抗病毒治疗、免疫抑制剂减停、局部手术切除以及传统的化疗外,单克隆抗体、过继性T细胞免疫治疗也带来了深远的影响.文章就allo-HSCT后EBV-PTLD治疗方面最新进展进行综述.Epstein-Barr virus （EBV） related post-transplant lymphoproliferative diseases （EBV-PTLD） is a rare and deadly complication after allogeneic hematopoietic stem cell transplantation （allo-HSCT）. The clinical manifestations often show the unexplained fever, swollen lymph nodes, hepatosplenomegaly, pharyngitis, and central nervous system symptoms, with rapid disease progression and high fatality rate. As allo-HSCT for treatment of complex and refractory hemopathy has made a great progress, the prevention of graft versus host disease （GVHD） requires more application of immune inhibitors, resulting in an increasing incidence rate of PTLD. In addition to conventional treatments, such as antiviral therapy, reduction of immune suppression , local surgery and traditional chemotherapy, monoclonal antibodies and adoptive immunotherapy with T-cells for treatment of PTLD have brought a profound influence. This paper reviews the latest progress of treatment of EBV-PTLD.

关 键 词：EB病毒相关的淋巴细胞增殖性疾病 异基因造血干细胞移植 治疗进展 

分 类 号：R457.7[医药卫生—治疗学] R733[医药卫生—临床医学]